Postoperative risk assessment remains an important variable in the effective treatment of prostate cancer. There is an unmet clinical need for a test with the potential to enhance the Gleason grading system with novel features that more accurately reflect a personalized prediction of clinical failure.
A prospectively designed retrospective study utilizing 892 patients, post radical prostatectomy, followed for a median of 8 years. In training, using digital image analysis to combine microscopic pattern analysis/machine learning with biomarkers, we evaluated Precise Post-op model results to predict clinical failure in 446 patients. The derived prognostic score was validated in 446 patients. Eligible subjects required complete clinical-pathologic variables and were excluded if they had received neoadjuvant treatment including androgen deprivation, radiation or chemotherapy prior to surgery. No patients were enrolled with metastatic disease prior to surgery. Evaluate the assay using time to event concordance index (C-index), Kaplan–Meier, and hazards ratio.
In the training cohort (n = 306), the Precise Post-op test predicted significant clinical failure with a C-index of 0.82, [95% CI: 0.76–0.86], HR:6.7, [95% CI: 3.59–12.45], p < 0.00001. Results were confirmed in validation (n = 284) with a C-index 0.77 [95% CI: 0.72–0.81], HR = 5.4, [95% CI: 2.74–10.52], p < 0.00001. By comparison, a clinical feature base model had a C-index of 0.70 with a HR = 3.7. The Post-Op test also re-classified 58% of CAPRA-S intermediate risk patients as low risk for clinical failure.
Precise Post-op tissue-based test discriminates low from intermediate high risk prostate cancer disease progression in the postoperative setting. Guided by machine learning, the test enhances traditional Gleason grading with novel features that accurately reflect the biology of personalized risk assignment.
Access optionsAccess options
Subscribe to Journal
Get full journal access for 1 year
only $131.00 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
We would like to thank members of the Biorepository and Pathology Core and all support personnel in the Department of Pathology at the Icahn School of Medicine at Mt. Sinai. We would also like to acknowledge both Roswell Park Cancer Center and the Henry Ford Hospital for access to their respective prostatectomy tissue cohorts.
The study was funded by the Icahn School of Medicine at Mt. Sinai but Mt. Sinai was not directly involved in the design and conduct of the study, the collection, management, analysis and interpretation of the data; preparation, review, or approval of the manuscript nor the decision to submit the manuscript for publication.
MJD, GF, RS, JZ, FMK, AT, and CCC contributed to study concept and design. MJD, GF, RS, GK, NG, EC, and FMK contributed to study development and methods, and GF, RS, NG, and EC collected the data. All authors analyzed and interpreted the data. FMK provided statistical and model development support. GK, NG, EC, and JZ provided administrative, technical, and material support. GF, JZ, RS, and MJD supervised the study. MJD, GF, and CCC wrote the manuscript. All authors have approved the final version of the manuscript.